Regeneron Pharmaceuticals (REGN) Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals has reported Non-Current Assets for 18 years, with the latest figure at $22.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 13.45% year-over-year to $22.7 billion; the trailing twelve-month figure through Mar 2026 stood at $88.7 billion (up 19.63% YoY), and the FY2025 full-year result was $22.5 billion, up 18.0% from the prior year.
• Non-Current Assets for Q1 2026 stood at $22.7 billion, up from $22.5 billion in the prior quarter.
• The five-year high for Non-Current Assets was $22.7 billion in Q1 2026, with the low at $11.7 billion in Q2 2022.
• Average Non-Current Assets over 5 years is $16.6 billion, with a median of $15.5 billion recorded in 2024.
• Year-over-year, Non-Current Assets soared 56.05% in 2022 and increased 2.03% in 2023.
• Tracing REGN's Non-Current Assets over 5 years: stood at $13.3 billion in 2022, then climbed by 2.03% to $13.6 billion in 2023, then jumped by 40.42% to $19.1 billion in 2024, then climbed by 18.0% to $22.5 billion in 2025, then advanced by 0.54% to $22.7 billion in 2026.
• The last three Non-Current Assets figures came in at $22.7 billion (Q1 2026), $22.5 billion (Q4 2025), and $22.2 billion (Q3 2025), per Business Quant data.

Peer Comparison